Vicuron reiterated by Stanford at hold

Vicuron Pharmaceuticals Inc. was reiterated by Stanford Group Co. analysts Dallas Webb and Aaron Reames at a hold rating following second-quarter results, noting that the pending acquisition by Pfizer Inc. remains in the background. Vicuron shares Friday were down $0.10, or 0.35%, at $28.10 on volume of 971,722 shares versus the three-month running average of 1,179,010 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.